ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on

ADC Therapeutics to Host Fourth Quarter

Financial Results Conference Call on March

Lausanne, Switzerland, March 11, 2021 - ADC

Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and

commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies

and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 18, 2021 at 8:30

a.m. ET to report financial results for the fourth quarter and year-end 2020 and provide business updates.

To access the live call, please dial 833-303-1198

(domestic) or +1-914-987-7415 (international) and provide conference ID 4985202. A live

webcast of the presentation will be available under "Events and Presentations" in the Investors section of the

ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be

available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics SA (NYSE: ADCT) is a late clinical-stage oncology-focused

biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates (ADCs)

for patients with hematological malignancies and solid tumors. The Company has created a deep clinical pipeline by combining its

decades of experience and strategic target selection with proprietary next-generation pyrrolobenzodiazepine (PBD) technology. The

Company's Biologics License Application for its lead product candidate, loncastuximab tesirine (Lonca, formerly ADCT-402)

for the treatment of relapsed or refractory diffuse large B-cell lymphoma was given priority review status by the U.S. Food and

Drug Administration and a Prescription Drug User Fee Act (PDUFA) target date of May 21, 2021. The Company's second lead product

candidate, camidanlumab tesirine (Cami, formerly ADCT-301), is being evaluated in a 117-patient pivotal Phase 2 clinical trial

for the treatment of relapsed or refractory Hodgkin lymphoma.

ADC Therapeutics is based in Lausanne (Biop le), Switzerland

and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and

follow the Company on Twitter and LinkedIn.

Tel.: +44 7879 627205

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 973-768-2170